In Vivo Imaging Facility

摘要：在活体成像设备(IVIF)中 癌症治疗的进步需要开发新的治疗方法和最先进的成像技术 需要技术来评估对这些疗法的反应。希尔曼癌症中心(Hillman癌症中心) 成像设备(IVIF)提供了追踪分子生物标记物的新的定量成像技术 与有效癌症治疗相关的事件和免疫治疗反应。先进成像技术的验证 需要特定于相关细胞过程的技术来检测和测量 新的抗癌疗法和测量早期杀瘤反应。作为这个设施的一部分，PET示踪器 靶向肿瘤微环境中的各种肿瘤标志物和免疫细胞，以及互补 光学和磁共振方法正在开发，以灵敏和特异地量化药物-癌细胞 互动。IVIF为在活体啮齿动物模型中测试PET示踪剂提供了关键的共享资源 癌症和通过定量成像试验在人类身上验证有前途的药物。该计划的总体目标 IVIF将为肝细胞癌研究人员提供临床前和临床影像服务，以协助可视化 生物标记物的作用机制，提供疾病早期检测和监测治疗的方法 功效。IVIF支持HCC的所有7个项目，并在#年出版了影响较大的出版物 《免疫》、《癌细胞》、《神学》和《自然通讯》等期刊。IVIF有76个用户 其中66人是肝细胞癌调查人员。在66名肝细胞癌用户中，42人获得了同行评审的资金。 IVIF的具体目标是：(1)使用单一的 临床和临床前的模式或组合；(2)提供无创成像 为监测人类和动物癌症模型的疗效提供服务；(3)提供标准 影像评估服务，评估所有类型的治疗反应，使用FDA批准的 标准成像评估标准；(4)提供并纳入放射组学等新的成像分析方法 用于临床和临床前肿瘤特征的放射基因组学；以及(5)开发新的成像技术 用于临床和临床前的算法、高级成像分析、放射性示踪剂和造影剂 用于监测和评估治疗反应的肿瘤学成像和靶向放射性核素治疗的试剂。 主要服务包括：(1)用于人体PET-CT和PET-MRI的PET放射性示踪剂的开发和生产；(2) 临床前PET-CT和癌症治疗期间生物标记物表达的临床或临床前评估； 以及(3)开发利用PET-CT、CT、 和/或MRI，通过使用分子成像、标准成像评估、肿瘤体积测量、 放射组学和放射基因组学。

Abstract: In Vivo Imaging Facility (IVIF) Advances in cancer management require the development of new therapies, and state-of-the-art imaging technologies are needed to assess response to those therapies. The Hillman Cancer Center (HCC) In Vivo Imaging Facility (IVIF) provides novel quantitative imaging techniques that trace biomarkers of molecular events and immunotherapy response associated with effective cancer therapy. Validation of advanced imaging techniques that are specific for relevant cellular processes are required to detect and measure the efficacy of novel anticancer therapies and measure early tumoricidal response. As part of this facility, PET tracers targeting various tumor markers and immune cells in the tumor microenvironment, as well as complementary optical and MR methodologies, are being developed to sensitively and specifically quantify drug-cancer cell interactions. The IVIF provides a critical shared resource for testing PET tracers in in vivo rodent models of cancer and validating promising agents in humans through quantitative imaging trials. The overall goal of the IVIF is to provide pre-clinical and clinical imaging services to HCC investigators to assist in visualizing mechanisms of biomarker action, provide approaches for early disease detection, and monitor therapeutic efficacy. The IVIF supports all 7 programs at HCC, and has contributed to high impact publications in Immunity, Cancer Cell, Theranostics and Nature Communications, among other journals. IVIF had 76 users of which 66 were HCC investigators. Of the 66 HCC users, 42 had peer-reviewed funding. The Specific Aims of the IVIF: (1) Assess biomarker expression throughout cancer treatment using a single modality or a combination of modalities, both clinically and pre-clinically; (2) provide non-invasive imaging services for monitoring therapeutic efficacy in humans and animal models of cancer; (3) provide standard imaging assessment services to evaluate all types of treatment response using the FDA-approved and other standard imaging assessment criteria; (4) provide and incorporate novel imaging analytics such as radiomics and radiogenomics for clinical and preclinical tumor characterizations; and (5) develop novel imaging algorithms, advanced imaging analytics, radiotracers, and contrast agents for clinical and pre-clinical oncological imaging to monitor and evaluate treatment response and agents for targeted radionuclide therapy. Key Services Include: (1) PET radiotracer development and production for human PET-CT and PET-MRI; (2) pre-clinical PET-CT and clinical or preclinical assessment of biomarker expression during cancer treatment; and (3) developing methods for monitoring drug treatments and other types of therapy with PET-CT, CT, and/or MRI through the use of molecular imaging, standard imaging assessments, tumor volumetrics, radiomics and radiogenomics.